Le secteur de la santé et des sciences de la vie croît inexorablement. C’est aujourd’hui une industrie qui pèse plusieurs milliards de dollars. En 2016, les entreprises actives dans ce domaine ont affiché des ventes à hauteur de 140 milliards de dollars et leurs bénéfices ont plus que doublé par rapport à 2010. Les secteurs pharmaceutique, chimique, ainsi que ceux des technologies médicales et du dépistage, sont devenus la principale industrie d’exportation de la Suisse.

The healthcare and life science sector is growing inexorably and is now a multi-billion dollar industry. In 2016 the companies in this sector posted sales of USD 140 billion, and their profitability more than doubled by comparison with 2010. The pharmaceutical, diagnostics, medtech and chemical sectors have become Switzerland’s most powerful export industry and significant number of approved medications and diagnostics contain biotech elements.
 

A happy coincidence brought Dr Markus Rimann from ZHAW Waedenswil together with Dr Andreas Meyer from the start-up FGen and PD Dr Emanuela Felley-Bosco, Molecular Oncologist at Zurich University Hospital, to develop a technology platform for the manufacture and high throughput analysis of single mesothelioma spheroids. Armin Picenoni, former student in Chemistry for the Life Sciences at ZHAW, confirmed everything in writing his Master Thesis on this Innosuisse project.

Bioprinting is the technology of choice for realizing functional tissues such as vascular system, muscle, cartilage and bone. In the future, bioprinting will influence the way we engineer tissues and bring it to a new level of hysiological relevance. That was the topic of the 2017 TEDD Annual Meeting at ZHAW Waedenswil on 8th and 9th November. In an exciting workshop, the two companies regenHU Ltd. and CELLINK gave us an insight into highly topical applications and collaborations in this domain.

When an innovative technology is going to be implemented in hospitals, medical practices or pharmacies, it often does not appear really new to researchers. It is the implementation itself and the domain where it is used that are at the core of innovation. That’s why the SWISS SYMPOSIUM in Point-of-Care Diagnostics (POCD) brings together key stakeholders from research and industry to clinical settings and patient care to exchange knowledge and experience and to stimulate activities in POCD.
 

It was a daring venture when Professor Fabian Fischer, lecturer in chemistry and biotechnology at HES-SO Valais/Wallis, organized a Microbial Fuel Cell Workshop at EXPO 2017 in Astana, the capital of Kazakhstan. This first world exhibition to be held in Central Asia (from 10 June to 1 September) is dedicated to ‘Future Energy’ and showcased Switzerland as an innovative country for energy efficiency, renewable energies and global water management.

The TEDD & 3R (Refine, Reduce and Replace animal experimentation) conference was organized by TEDD (Tissue Engineering for Drug Development and Substance Testing) together with Animalfree Research (www.animalfree-research. org). The Foundation has the vision of a world without animal experiments, which is why it supports research into alternative methods and their further development. As soon as procedures not entailing the use of an animal are available, the law requires that they be applied.A few questions to Dr.

On July 4th 2017 the University of Applied Sciences Northwestern Switzerland and the University Hospital Basel presented in collaboration with BaselArea.swiss the symposium „3D Printing for Life Sciences“ at the School of Life Sciences in Muttenz.

For further information please have a look on:

https://www.baselarea.swiss/baselarea-swiss/channels/innovation-events/2017/07/3d-printing-for-life-sciences.html  (symposium)

 “This ‘telephone’ has too many shortcomings to be seriously considered as ameans of communication. The device is inherently of no value to us.” -  This was an internal memo written by WesternUnion in 1876. That’sright. Without efficient knowledge sharing and technology transfer,even the best scientific development may prove to be adamp squib for along time. The Basel Life Science Week was created in order topromotescientificandeconomicexchangeandpavetheway for innovative ideas. That’swhy NTN Swiss Biotech has moved its traditional ‘Olten Meeting’ to the Basel Life Science Week.... Read more ...

BioTech 2016 Conference at ZHAW Waedenswil

“Keep up with today’s single-use technology standard but also remain one step ahead” – that could have been the motto of the BioTech 2016 conference at ZHAW Waedenswil on September 5 and 6, which brought together manufacturers, suppliers, users, regulatory specialists and representatives of organizations in this field to implement single-use devices all over the world. It was an effectiveness analysis of the trend to replace reusable equipment in production facilities with singleuse components.

 In vitro diagnostics (IVD) has huge potential. Primary drivers in the global market are the patient’s awareness of infectious diseases, the introduction of advanced molecular and tissue diagnostic tests for patient-stratified and targeted anti-cancer therapy and, last but not least, the growing geriatric population. Rapid progress in device miniaturization and information technology (IT) offers new possibilities in decentralized testing. Grand View Research Inc. expects the global market for IVD to reach US $ 74.3 billion by 2020.

Prof. Fabian Fischer from the HES-SO Valais-Wallis is spezialized in microbial fuel cells for novel applications that meet the challenge of producing renewable energies.

Michael Raghunath from the National University of Singapore will take over the professorship from Ursula Graf-Hausner in cell culture technology and tissue engineering at ZHAW Wädenswil

Biosorption at the HES-SO Valais-Wallis Sion - Looking for Partners to Implement Innovative Technologies

Avicenna Oncology and the Big Challenge: The Fight against Agressive and Resistant Cancers